The importance of selecting a proper biological milieu for protein corona analysis in vitro: Human plasma versus human serum.
暂无分享,去创建一个
Raehyun Kim | Morteza Mahmoudi | Vahid Mirshafiee | M. Mahmoudi | Raehyun Kim | Vahid Mirshafiee | M. Kraft | Mary L Kraft
[1] H. Fuchs,et al. Reaction of human macrophages on protein corona covered TiO₂ nanoparticles. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[2] Ching-Seng Ang,et al. Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas. , 2015, ACS nano.
[3] Weihong Tan,et al. Fluorescent nanoparticles for multiplexed bacteria monitoring. , 2007, Bioconjugate chemistry.
[4] Dan Peer,et al. Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.
[5] Analysis of macrophage phagocytosis: quantitative assays of phagosome formation and maturation using high-throughput fluorescence microscopy. , 2009, Methods in molecular biology.
[6] M. Grzelczak,et al. Glycans as biofunctional ligands for gold nanorods: stability and targeting in protein-rich media. , 2015, Journal of the American Chemical Society.
[7] Wenwan Zhong,et al. Size and Surface Functionalization of Iron Oxide Nanoparticles Influence the Composition and Dynamic Nature of Their Protein Corona , 2014, ACS applied materials & interfaces.
[8] C. Mirkin,et al. Spherical nucleic acid nanoparticle conjugates enhance G-quadruplex formation and increase serum protein interactions. , 2014, Angewandte Chemie.
[9] K. Kwiatkowska,et al. Binding of IgG-Opsonized Particles to FcγR Is an Active Stage of Phagocytosis That Involves Receptor Clustering and Phosphorylation1 , 2005, The Journal of Immunology.
[10] J. Vallée,et al. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. , 2014, Nanoscale.
[11] Marilena Hadjidemetriou,et al. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles. , 2015, ACS nano.
[12] Iseult Lynch,et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.
[13] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[14] K. Dawson,et al. Time and space resolved uptake study of silica nanoparticles by human cells. , 2011, Molecular bioSystems.
[15] Paolo Bergese,et al. Surfactant titration of nanoparticle-protein corona. , 2014, Analytical chemistry.
[16] P. Charoenphol,et al. Plasma Protein Corona Modulates the Vascular Wall Interaction of Drug Carriers in a Material and Donor Specific Manner , 2014, PloS one.
[17] Timothy D Veenstra,et al. Serum and plasma proteomics. , 2007, Chemical reviews.
[18] Iseult Lynch,et al. The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.
[19] Kenneth A. Dawson,et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.
[20] G. J. Cannon,et al. The macrophage capacity for phagocytosis. , 1992, Journal of cell science.
[21] Parag Aggarwal,et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.
[22] M. Mahmoudi,et al. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. , 2016, Biomaterials.
[23] M. Mann,et al. Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein*S , 2005, Molecular & Cellular Proteomics.
[24] E. Peterhans,et al. Fibrinogen association with human monocytes: evidence for constitutive expression of fibrinogen receptors and for involvement of Mac-1 (CD18, CR3) in the binding. , 1988, Biochemical and biophysical research communications.
[25] Jin Xie,et al. Nanoparticle-based theranostic agents. , 2010, Advanced drug delivery reviews.
[26] Warren C W Chan,et al. Nanoparticle-blood interactions: the implications on solid tumour targeting. , 2015, Chemical communications.
[27] Iseult Lynch,et al. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[28] Karen L Wooley,et al. Design of polymeric nanoparticles for biomedical delivery applications. , 2012, Chemical Society reviews.
[29] Kenneth A Dawson,et al. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. , 2013, Journal of the American Chemical Society.
[30] P. Mannucci,et al. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen , 1988, The Journal of cell biology.
[31] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[32] K. Higaki,et al. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. , 2007, International journal of pharmaceutics.
[33] K. Dawson,et al. Characterization of the bionano interface and mapping extrinsic interactions of the corona of nanomaterials. , 2015, Nanoscale.
[34] Jianjun Cheng,et al. Protein corona significantly reduces active targeting yield. , 2013, Chemical communications.
[35] Bo Yan,et al. Fabrication of Corona-Free Nanoparticles with Tunable Hydrophobicity , 2014, ACS nano.
[36] Philip M. Kelly,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[37] Zhengping Zhang,et al. Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy. , 2015, ACS nano.
[38] J. Richie,et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[39] Warren C W Chan,et al. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. , 2012, Chemical Society reviews.
[40] L. Leive,et al. Variants deficient in phagocytosis of latex beads isolated from the murine macrophagelike cell line J774 , 1984, The Journal of cell biology.
[41] Parag Aggarwal,et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.
[42] Sara Linse,et al. Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[43] M. Mahmoudi,et al. Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.
[44] Sara Linse,et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.
[45] A. S. Moses,et al. Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.
[46] James Chen Yong Kah,et al. Optimizing the properties of the protein corona surrounding nanoparticles for tuning payload release. , 2013, ACS nano.
[47] B. Forbes,et al. Surface chemistry of photoluminescent F8BT conjugated polymer nanoparticles determines protein corona formation and internalization by phagocytic cells. , 2015, Biomacromolecules.
[48] M. Hashida,et al. Important role of serum proteins associated on the surface of particles in their hepatic disposition. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[49] Warren C W Chan,et al. The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.
[50] Li Tang,et al. Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. , 2012, ACS nano.
[51] Kenneth A Dawson,et al. Suppression of nanoparticle cytotoxicity approaching in vivo serum concentrations: limitations of in vitro testing for nanosafety. , 2014, Nanoscale.
[52] Murali M. Yallapu,et al. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. , 2015, Biomaterials.
[53] Kenneth A. Dawson,et al. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. , 2012, ACS nano.
[54] Morteza Mahmoudi,et al. Cell "vision": complementary factor of protein corona in nanotoxicology. , 2012, Nanoscale.
[55] Iseult Lynch,et al. What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.
[56] P. Ralph,et al. Functional macrophage cell lines transformed by abelson leukemia virus , 1978, Cell.